Explore RXRX's upcoming H2'25 trial updates for REC-4881 in familial adenomatous polyposis and REC-617.

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -17.14% and +33.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for ...

SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based company said it had ...

Recursion Pharmaceuticals grew its share prices for a fourth straight day on Monday, adding 9.59 percent to close at $6.40 apiece as investors repositioned portfolios ahead of its second quarter ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds. Earlier on June 6, a significant advancement in drug discovery was announced with the ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. Quiver AI Summary MIT and Recursion have released Boltz-2 ...

Prime Intellect has released INTELLECT-2, a 32 billion parameter language model trained using fully asynchronous reinforcement learning across a decentralized network of compute contributors ...

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 ...